Novel molecular markers of lung cancer risk and survival

肺癌风险和生存的新型分子标志物

• 批准号: nhmrc : GNT1050198
• 负责人: Dr Allison Hodge
• 金额: $ 82.48万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-molecular-markers-risk-survival/1344515
• 关键词: Novel; molecular; markers; lung; cancer

Lung cancer remains the most lethal cancer worldwide, yet little is known of the risk factors beyond that of tobacco smoking and certain occupational exposures. We have assembled a large international consortium comprising 24 cohort studies and over 10,000 to validate associations between B-vitamins and lung cancer risk particularly in never and former smokers. We propose to expand this study and use the Melbourne Collaborative Cohort Study and the rest of the consortium to identify novel biomarkers of risk and survival.

肺癌仍然是全世界最致命的癌症，但除了吸烟和某些职业暴露之外，人们对肺癌的危险因素知之甚少。我们组建了一个由 24 项队列研究和 10,000 多项队列研究组成的大型国际联盟，以验证 B 族维生素与肺癌风险之间的关联，特别是在从未吸烟者和既往吸烟者中。我们建议扩大这项研究，并利用墨尔本合作队列研究和该联盟的其他成员来确定风险和生存的新生物标志物。